Vanda Pharmaceuticals (NASDAQ:VNDA) Receives New Coverage from Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research report issued on Tuesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald increased their price target on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st.

Vanda Pharmaceuticals Price Performance

Shares of VNDA stock opened at $4.50 on Tuesday. The company’s fifty day moving average price is $5.09 and its two-hundred day moving average price is $5.19. The firm has a market capitalization of $262.31 million, a P/E ratio of -56.25 and a beta of 0.77. Vanda Pharmaceuticals has a 12 month low of $3.30 and a 12 month high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) EPS for the quarter. Vanda Pharmaceuticals had a negative return on equity of 2.01% and a negative net margin of 6.00%. The business had revenue of $50.47 million during the quarter. On average, sell-side analysts anticipate that Vanda Pharmaceuticals will post -0.49 EPS for the current year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. SageView Advisory Group LLC acquired a new stake in shares of Vanda Pharmaceuticals during the 1st quarter valued at $34,000. Meeder Asset Management Inc. acquired a new stake in shares of Vanda Pharmaceuticals during the second quarter worth $39,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Vanda Pharmaceuticals by 65.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 11,045 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 4,387 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Vanda Pharmaceuticals in the 2nd quarter valued at $61,000. Finally, Price T Rowe Associates Inc. MD increased its stake in Vanda Pharmaceuticals by 18.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 2,425 shares in the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.